On September 5, 2018 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that data from the PD-(L)1 refractory non-small cell lung cancer (NSCLC) cohort of ENCORE 601 will be presented at the upcoming International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC) being held September 23-26, 2018 in Toronto, Canada (Press release, Syndax, SEPT 5, 2018, View Source [SID1234529292]). ENCORE 601 is a Phase 1b/2 trial evaluating the efficacy and safety of entinostat, the Company’s class I selective HDAC inhibitor, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, across multiple cohorts of PD-(L)1 treatment-naïve and pre-treated cancers, including NSCLC, melanoma and microsatellite stable colorectal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstract is available on the World Conference on Lung Cancer website at View Source Updated data will be presented at the conference.

Presentation Details

Title: Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy
Presenter: Matthew D. Hellmann, M.D., Memorial Sloan Kettering Cancer Center
Track: Advanced NSCLC
Session: OA05 – Clinical Trials in IO
Presentation Number: OA05.01
Date and Time: September 24, 2018 1:30 – 1:40 PM ET

On September 5, 2018 Exelixis, Inc. (NASDAQ: EXEL) reported that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Morgan Stanley Global Health Care Conference taking place September 12-14 in New York, NY (Press release, Exelixis, SEPT 5, 2018, View Source;p=irol-newsArticle&ID=2366220 [SID1234529291]). The Exelixis presentation is scheduled for 1:05 PM EDT / 10:05 AM PDT on Wednesday, September 12, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

On September 5, 2018 Cytokinetics, Inc. (Nasdaq: CYTK) reported that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 at 11:40 AM ET at the Grant Hyatt in New York City (Press release, Cytokinetics, SEPT 5, 2018, View Source [SID1234529290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event.

On September 5, 2018 Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, reported that company management will participate in a fireside chat at the 16th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 at 1:40 p.m. ET (Press release, Blueprint Medicines, SEPT 5, 2018, View Source [SID1234529289]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.

On September 5, 2018 Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, reported that Ivan Bergstein, M.D., Stemline’s CEO, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 9:10 AM ET at the St. Regis New York Hotel (Press release, Stemline Therapeutics, SEPT 5, 2018, View Source [SID1234529288]). A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!